NIH PAR · NCI · R01
PAR-25-336: Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
Through this Notice of Funding Opportunity (NOFO), entitled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), the National Cancer Institute (NCI) encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are designed to mature experimental nanomedicines relying on nanoparticles and nano-devices which demonstrate strong potential to improve cancer treatment effectiveness due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed…
- NOFO number
- PAR-25-336
- Type
- PAR
- Activity code
- R01
- Primary institute
- NCI · National Cancer Institute
- Clinical trials
- Not Allowed
- Posted
- Dec 16, 2024
- Opens
- Apr 19, 2025
- Expires
- Nov 16, 2027
PAR-25-336 due dates
3 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| May 19, 2025 | May 19, 2025 | Not Applicable | November 2025 | January 2026 | April 2026 |
| November 17, 2025 | November 17, 2025 | Not Applicable | March 2026 | May 2026 | July 2026 |
| May 18, 2026 | May 18, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| November 16, 2026 | November 16, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| May 17, 2027 | May 17, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
| November 15, 2027 | November 15, 2027 | Not Applicable | March 2028 | May 2028 | July 2028 |
Projects funded under PAR-25-336
NIH RePORTER lists 3 projects funded under PAR-25-336 in FY2022–FY2026, with $2.0M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
3
Distinct projects, FY2022–FY2026
New awards
3
Type 1 (new project) award records
NIH funding
$2.0M
Award dollars under PAR-25-336, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 3 | 3 | $2.0M |
Institutions with the most funding
- Sloan-Kettering Inst Can Research$709K · 1 project
- University of Houston$657K · 1 project
- Massachusetts General Hospital$651K · 1 project
Funding institutes
- NCI$2.0M · 3
Activity codes funded
- R013 records
Most recent new awards
- P-Selectin-Targeting Nanoparticles to Potentiate Cancer Immunotherapy (opens NIH RePORTER)
Sloan-Kettering Inst Can Research · 1R01CA305504-01A1 · NCI · Notice Aug 28, 2026
$709KR01
- TOWARD TRANSLATION OF NANOPHOTONIC SINGLE EXOSOME LIQUID BIOPSY FOR HEPATOCELLULAR CARCINOMA SCREENING AND DIAGNOSIS (opens NIH RePORTER)
University of Houston · 1R01CA316276-01 · NCI · Notice Aug 19, 2026
$657KR01
- A CRISPR-based sensitive liquid biopsy for endometrial cancer using tumor-derived hallmarks (CRISPR SLEUTH) (opens NIH RePORTER)
Massachusetts General Hospital · 1R01CA310785-01 · NCI · Notice May 18, 2026
$651KR01
What its predecessor PAR-22-071 funded
PAR-25-336 reissues PAR-22-071. Its funding history is the best guide to who wins under this program: 10 projects and $20.7M in FY2022–FY2026.
Projects funded
10
Distinct projects, FY2022–FY2026
New awards
10
Type 1 (new project) award records
NIH funding
$20.7M
Award dollars under PAR-22-071, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 6 | 6 | $3.6M |
| FY2024 | 8 | 2 | $4.6M |
| FY2025 | 10 | 2 | $8.1M |
| FY2026 | 7 | 0 | $4.3M |
Institutions with the most funding
- Vanderbilt University Medical Center$2.6M · 1 project
- University of California, San Francisco$2.5M · 1 project
- University of Washington$2.4M · 1 project
- University of Tx MD Anderson Can Ctr$2.2M · 1 project
- Cedars-Sinai Medical Center$2.2M · 1 project
- University of California Los Angeles$2.1M · 1 project
- University of Pennsylvania$1.9M · 1 project
- University of California at Davis$1.9M · 1 project
Most recent new awards
- Translational development of osteosarcoma (OS) extracellular vesicle (EV) matrix metalloproteinase (MMP) Activity Assay for assessing patient treatment responses (opens NIH RePORTER)
University of California Los Angeles · 1R01CA298883-01 · NCI · Notice Aug 18, 2025
$2.1MR01
- Interstitial Chemophototherapy as an Intervention in Locally Advanced Pancreatic Cancer (opens NIH RePORTER)
State University of New York at Buffalo · 1R01CA298877-01 · NCI · Notice Apr 11, 2025
$677KR01
- Designer extracellular vesicles for cancer therapy (opens NIH RePORTER)
University of Pennsylvania · 1R01CA284182-01A1 · NCI · Notice Jul 8, 2024
$663KR01
- Development of novel nanotherapeutics to overcome therapy resistance using canine brain tumor as a spontaneous model (opens NIH RePORTER)
University of California at Davis · 1R01CA294557-01 · NCI · Notice Jun 24, 2024
$635KR01
- Targeting tumor microenvironment by nanoimmunodrugs for glioma treatment (opens NIH RePORTER)
Cedars-Sinai Medical Center · 1R01CA284247-01 · NCI · Notice Sep 19, 2023
$577KR01
- Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy (opens NIH RePORTER)
University of Tx MD Anderson Can Ctr · 1R01CA284108-01 · NCI · Notice Jul 18, 2023
$568KR01
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-336. Contact the program officer at the institute that fits your research before applying.
- NCI · National Cancer Institute
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are limited to 475,000 in direct costs per year and need to reflect the actual needs of the proposed project.
- Project period
- The maximum project period is 4 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-22-071.
Other open NOFOs for R01
- PAR-27-072Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-25-337Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-25-338Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PAR-25-243Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PA-25-172Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-24-311Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.